Correlation of FAK+MEK combination activity with molecular characterization of GBM stem cell lines demonstrates no association with the transcriptomic subtype or mutation status of major tumor drivers (NF1, EGFR, B-RAF), indicating this combination may serve a wider population of GBM patients than previously anticipated. The gene discussed is PTK2; the disease is glioblastoma.